Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat Mesilate in Severe Infection-associated Coagulopathy
NCT06078839Phase 4Not yet recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in sepsis-induced coagulopathy (SIC) comparing Placebo control group with Nafamostat mesilate treatment group (2 arms). Primary endpoint: All-cause mortality in ICU at 7 days. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
Nafabelltan
03
Conditions
sepsis-induced coagulopathy (SIC)
Beyond the preview
Go deeper on NCT06078839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078839.